IDT Australia
ASX:IDTMelbourne, Australia· Est.
Australian CDMO delivering full‑spectrum cGMP API and dosage‑form manufacturing for pharma partners.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Australian CDMO delivering full‑spectrum cGMP API and dosage‑form manufacturing for pharma partners.
OncologyOphthalmologyNeurologyMetabolicCardiovascular
Technology Platform
Modular cGMP manufacturing platform covering API synthesis, high‑potency/controlled‑substance production, and sterile fill‑and‑finish for oral, injectable and radiopharmaceutical dosage forms.
Opportunities
Rising demand for outsourced manufacturing of advanced therapies and high‑potency APIs, combined with Australian R&D tax incentives, offers strong growth potential.
Risk Factors
Regulatory shifts, capacity constraints, and intense competition from larger global CDMOs could impact market share.
Competitive Landscape
Competes with global CDMOs such as Lonza, Catalent, and Samsung Biologics; differentiates through high‑containment capabilities, flexible modular facilities, and Australian regulatory advantages.